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Structural and dynamic insights into the energetics
of activation loop rearrangement in FGFR1 kinase
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Protein tyrosine kinases differ widely in their propensity to undergo rearrangements of the
N-terminal Asp–Phe–Gly (DFG) motif of the activation loop, with some, including FGFR1
kinase, appearing refractory to this so-called ‘DFG ﬂip’. Recent inhibitor-bound structures
have unexpectedly revealed FGFR1 for the ﬁrst time in a ‘DFG-out’ state. Here we use
conformationally selective inhibitors as chemical probes for interrogation of the structural
and dynamic features that appear to govern the DFG ﬂip in FGFR1. Our detailed structural and
biophysical insights identify contributions from altered dynamics in distal elements, including
the aH helix, towards the outstanding stability of the DFG-out complex with the inhibitor
ponatinib. We conclude that the aC-b4 loop and ‘molecular brake’ regions together impose
a high energy barrier for this conformational rearrangement, and that this may have
signiﬁcance for maintaining autoinhibition in the non-phosphorylated basal state of FGFR1.
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R
eceptor tyrosine kinases (RTKs) wield exquisite control
over cell differentiation, fate, metabolism and homeostasis.
Dysregulation of RTK signalling plays a signiﬁcant role in
the pathogenesis of disease conditions ranging from cancers to
inﬂammatory and neurodegenerative illnesses. Hence, it is not
surprising that over the past two decades they have become one of
the most important classes of enzyme to be exploited as targets
for drug discovery1. Conformational plasticity is an essential
feature of kinase function and regulation. Inhibitors of kinase
domain catalytic activity developed in the course of drug
discovery programmes have drawn attention to the importance
of mobility in the conserved Asp–Phe–Gly (DFG) tripeptide
motif at the proximal end of the activation loop (A-loop). The
majority of kinase inhibitors described to date bind competitively
with ATP to a presumed basal state conformation (termed ‘DFG-
in’ or the ‘type I’ binding mode) in which the Phe side chain of
the DFG motif resides in a hydrophobic pocket deep within the
kinase fold. An early insight into the role of the DFG motif as a
conformational switch was provided by the structure of the
tyrosine kinase Bcr-Abl complexed with the inhibitor STI-571
(imatinib)2. This structure indicated that the DFG motif
undergoes a conformational rearrangement whereby the Phe
side chain is ﬂipped out of its hydrophobic pocket, vacating space
for insertion of an aromatic moiety of the inhibitor. ‘DFG-out’
conformations have since been observed in many kinases, both
inhibitor bound3 and, occasionally, in the unbound state4–8. The
DFG-out state is catalytically inactive, since it is sterically
incompatible with cofactor and substrate binding, and in some
kinases may natively contribute to autoinhibition8,9. Indeed,
several so-called ‘type II’ inhibitors, that bind to and stabilize the
DFG-out form of a number of kinases, have been described10. An
intriguing anecdotal observation from drug discovery is that it is
relatively easy to identify type II (as opposed to type I) inhibitors
against some kinases, but difﬁcult or impossible for others. A
plausible explanation for these differences may lie in the chemical
space populated by screening libraries, favouring type I binding
modes against some kinases and type II inhibitors in others.
Alternatively, there could be speciﬁc structural or dynamic
differences between individual kinases that relatively favour one
or other binding mode. This conformational balance has been
referred to as the ‘DFG-out propensity’11. Evidence has been
advanced recently that DFG-out propensity and/or the rates of
interconversion between DFG-in and DFG-out may be inﬂuenced
by the side chain properties at, or adjacent to, particular points of
the regulatory or catalytic ‘spines’ of the kinase domain12.
Members of the FGFR family (FGFR1 to 4) are key mediators
of both developmental and disease-associated angiogenesis13
and are heavily implicated in the pathogenesis of tumour
vascularization in a number of different tumour types including
breast14, pancreatic15, prostate16 and ovarian17 carcinomas, as
well as being driving oncogenes for malignant transformation in
their own right13,18. Hence, they have been seen as attractive
targets for the development of therapeutic agents aimed at
inhibition of tumour growth and metastasis. Despite concerted
efforts to develop type II inhibitors of FGFR1 kinase in our own
drug discovery programme, we obtained only type I inhibitors as
conﬁrmed by X-ray crystallographic analysis of470 compounds,
and none of the 430 FGFR1 kinase structures in the Protein
Data Bank adopts the DFG-out conformation. Recently, however,
we observed that the Bcr-Abl inhibitor ponatinib (AP24534) also
binds potently to FGFR1 kinase, and moreover we and others
have now conﬁrmed that it binds to the DFG-out conformation
of FGFR kinases19–21. Intrigued by this ﬁnding, we embarked
on an investigation of the factors that underlie the seemingly
strong preference for the DFG-in state in FGFR1, using inhibitors
that stabilize the respective A-loop conformations as chemical
‘free-energy probes’. When compared with well-known type I
inhibitors, binding of ponatinib to FGFR1 revealed startling
differences in kinetic and thermodynamic behaviour associated
with the two binding modes. Our analysis of changes in protein
dynamics between the unbound, type I-bound and type II-bound
states, using both nuclear magnetic resonance (NMR) and
hydrogen–deuterium-exchange mass spectrometry (HDX-MS),
shows that both proximal and distal structural elements inﬂuence
activation loop conformational energetics in FGFR1.
Results
For our studies of the FGFR1 kinase domain, we have used a
construct spanning residues Ala458 to Glu765 of human FGFR1
that contains two mutations (Cys488Ala and Cys584Ser)
designed to stabilize the enzyme against covalent aggregation.
The protein is non-phosphorylated after co-expression with
PTP1B and puriﬁcation from Escherichia coli. An additional
mutation of the catalytic aspartate (Asp623Ala) was introduced
for NMR studies to increase further the yield of stable isotope-
labelled protein. Our previous studies have shown that this
mutation does not detectably perturb the structure of the FGFR1
kinase domain22. In addition, we have conﬁrmed using surface
plasmon resonance (SPR) that binding parameters for a close
analogue of the canonical FGFR1 inhibitor PD173074 (ref. 23;
henceforth referred to as PDA; Fig. 1a; Supplementary Fig. 1) are
unaltered for the Asp623Ala mutant relative to the kinase-active
form (data not shown).
Ponatinib-binding kinetics suggest a low DFG-out propensity.
On binding of ponatinib (Fig. 1a), and in contrast to the binding
of PDA, FGFR1 kinase domain was observed to adopt a DFG-out
conformation as determined by X-ray crystallography in our
laboratory and reported elsewhere19–21 (Fig. 1b,c). The reason
for the apparently refractory behaviour of FGFR1 towards
adopting ‘DFG-out’ has, however, remained elusive to date. We
hypothesized that an intrinsically low DFG-out propensity might
be the underlying reason, prompting us to compare the binding
kinetics of ponatinib (to date the only known high-afﬁnity type II
FGFR1 inhibitor) with those of representative type I inhibitors
(Supplementary Fig. 1a). A kinetic analysis using SPR highlights
the fact that while the type I inhibitors we investigated show fairly
uniformly fast association rate constants, the binding of ponatinib
is exceptionally slow (Fig. 1d, Supplementary Table 1). With
an association rate constant of 2.4 104M 1 s 1, it is B70
slower than that of PDA (kon¼ 1.6 106M 1 s 1), which has
almost identical afﬁnity to ponatinib. Notably, the comparable
afﬁnity of ponatinib (KD¼ 7.9 nM) and PDA (KD¼ 5.7 nM) for
FGFR1 is a result of the outstandingly long lifetime of the
ponatinib–FGFR1 complex: the dissociation rate constant for
ponatinib (koff¼ 1.9 10 4 s 1, corresponding to a half-life
(t1/2) for the complex ofB61min) isB50 slower than that for
PDA (koff¼ 9.2 10 3 s 1; t1/2¼ 1.3min). Slow rate constants
have previously been reported for type II inhibitors binding to a
number of kinases24–28. These observations have been interpreted
as consistent with a slow equilibrium between DFG-in and
DFG-out states, where the DFG-out conformation is sampled
only infrequently, accompanied in some cases by slow
interconversion of ligand conformations, as ,for example, in the
binding of analogues of BIRB-796 to p38 MAP kinase29. Recently,
Shan et al.11, using Abl kinase as a model system, suggested that
the DFG conformation is controlled by a protonation-dependent
energetic switch. According to that analysis, the acidity of the
DFG aspartate may be one factor that drives the equilibrium
between the DFG-in and DFG-out conformations. To investigate
whether protonation of the DFG aspartate also inﬂuences the
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8877
2 NATURE COMMUNICATIONS | 6:7877 | DOI: 10.1038/ncomms8877 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
DFG ﬂip in FGFR1, we derived the association rate constants of
the DFG-out inhibitor ponatinib and the DFG-in inhibitor PDA
as a function of pH. The rate of ponatinib binding to FGFR1
increased nearly sevenfold as pH decreased from 7.4 to 5.5
(Fig. 1e). Ponatinib is expected to be protonated on its terminal
methylpiperazinyl nitrogen across this pH range; thus, the pH
dependence very likely reports on the ionization state of Asp641,
giving a calculated effective pKa of 6.25, well above the
unperturbed range for aspartate. The observed variation in the
on-rate for binding to the DFG-out conformation as a function of
Asp641 ionization state lends support to the hypothesis that the
DFG ﬂip is rate-limiting on ponatinib association to FGFR1. In
contrast to ponatinib, the binding kinetics of PDA to FGFR1
showed no dependence on pH over a similar range (Fig. 1f),
which is consistent with the assumption that the binding of the
so-called DFG-in inhibitors is not affected by the conformation of
the DFG motif30.
Ponatinib binding is accompanied by an enthalpic penalty. The
apparently slow equilibrium between DFG-in and DFG-out
conformations in FGFR1 kinase suggests a high free-energy
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Figure 1 | Structural and kinetic characteristics of FGFR1 complexes with the type I and type II inhibitors PDA and ponatinib. (a) Chemical structures of
PDA and ponatinib. (b) Active site of FGFR1 kinase in complex with PDA (green carbons) as determined at 2.09Å resolution (Supplementary Table 5). The
hinge region (yellow) and A-loop (orange) are highlighted. Fo Fc OMIT electron density for PDA and the DFG motif is represented as a blue mesh
contoured at 3.0s. Polar interactions are indicated as dotted lines. (c) Active site of FGFR1 kinase in complex with ponatinib (grey carbons) as determined
at 2.33Å resolution, with Fo Fc OMITelectron density for ponatinib and the DFG motif represented as a blue mesh contoured at 3.0s. Colouring of FGFR1
as in b. (d) Kinetic value plot of association rate constant (kon) versus dissociation rate constant (koff). Rate constants were determined using SPR at 298K,
pH¼ 7.4. The afﬁnities (KD) were calculated from the equation KD¼ koff/kon and broken lines represent afﬁnity isotherms. Data represent geometric means
from at least three independent experiments; standard errors are shown as error bars (values and errors are presented in Supplementary Table 1). (e) The
association rate constant of ponatinib binding to FGFR1 as a function of pH, as measured by SPR at 298K. The red line represents the result of the non-
linear ﬁtting of the data to the 4 PL model (R2¼0.968; pKa(Asp641)¼6.25). (f) The association rate constant of PDA binding to FGFR1 as a function of pH,
as measured by SPR at 298K.
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barrier for the DFG ﬂip. We carried out a detailed analysis of the
changes in enthalpy and entropy that accompany ligand binding
to enhance our understanding. For the selected type I inhibitors,
isothermal titration calorimetry (ITC) experiments revealed
exothermic binding reactions (Fig. 2a, Supplementary Fig. 2,
Supplementary Table 2), and the derived binding afﬁnities were
largely in agreement with those determined by SPR. In contrast,
for ponatinib, which binds to FGFR1 in a DFG-out conformation,
the observed titration curve (Supplementary Fig. 2h) was of
poor quality and did not allow derivation of thermodynamic
parameters. As an alternative to ITC, we analysed kinetic
and equilibrium data from SPR as a function of temperature,
following the van’t Hoff method, to provide independent
thermodynamic characterization of binding events. For ponatinib
and two selected type I inhibitors (PDA and SU5402), the
derived binding enthalpies and entropies revealed another
marked difference between the type II inhibitor ponatinib
and the selected type I inhibitors (Fig. 2b, Table 1). In the case of
PDA and SU5402, van’t Hoff analysis conﬁrmed exothermic
binding enthalpies (PDA, DH¼  11.5 kcalmol 1; SU5402,
DH¼  14.2 kcalmol 1) and the data are in close agreement
with the DH values of  12.1 kcalmol 1 (PDA) and
 12.4 kcalmol 1 (SU5402) determined by ITC. Unexpectedly,
the type II inhibitor ponatinib showed an endothermic
DH value (DH¼ 10.1 kcalmol 1) that indicates enthalpically
unfavourable binding. Ponatinib and PDA exhibit comparable
van’t Hoff free energies of binding (Table 1) that are
consistent with their very similar afﬁnities measured directly
by SPR; however, breaking this down into enthalpic and
entropic components revealed signiﬁcant differences, as the
binding of PDA and ponatinib were determined to be enthalpy
driven and entropy driven, respectively. An endothermic
enthalpy, as observed for the equilibrium between free and
FGFR1-bound ponatinib, raises the possibility that the con-
formational rearrangement required to effect the DFG ﬂip in
FGFR1 may also be associated with an enthalpic penalty
(neglecting net contributions from protein–ligand and protein–
solvent interactions of ponatinib). Furthermore, we established
that the vascular endothelial growth factor receptor (VEGFR)
inhibitor tivozanib (AV-951) also binds to FGFR1 in a DFG-out
mode (KD¼ 1.3 mM by SPR) and does so endothermically by
van’t Hoff analysis (Supplementary Fig. 3), lending further sup-
port to the notion that this may be a signature of a DFG-out
binding mode for FGFR1, rather than a compound-speciﬁc
characteristic of ponatinib.
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Figure 2 | Thermodynamic data for inhibitors binding to FGFR1 kinase domain. (a) Thermodynamic signatures for type I inhibitors binding to FGFR1
derived by ITC at 298K. Data shown are arithmetic mean±s.d. from at least two independent experiments (values and errors are presented in
Supplementary Table 2). (b) van’t Hoff plot visualization of temperature-dependent FGFR1–ligand interactions measured by SPR for PDA (blue circles),
SU5402 (blue open squares) and ponatinib (red triangles). (c) Thermodynamic reaction pathway models for FGFR1 interacting with PDA (left) and
ponatinib (right). The reaction coordinate depicts the lowest energy continuous pathway between the free (centre of the ﬁgure) and bound states (left for
PDA complex; right for ponatinib complex) via the transition state, for free energy DG (green), enthalpy DH (blue) and entropy—TDS (red).
Table 1 | Standard enthalpies, entropies and Gibbs free
energies (kcalmol 1) for binding of the type I inhibitors,
PDA and SU5402, and the type II inhibitor ponatinib,
derived from non-linear van’t Hoff analysis of data in Fig. 2b.
Inhibitor DH0van’t Hoff TDS0van’t Hoff* DG0van’t Hoff* R2w
PDA  11.5±0.8 0.4±0.8  11.1±0.02 0.862
SU5402  14.2±0.8 4.8±0.8  9.5±0.02 0.983
Ponatinib 10.1±1.6  21.0±1.6  10.9±0.04 0.879
*Standard errors, T0¼ 298K.
wFrom non-linear ﬁtting of data in Fig. 3b.
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A large free-energy barrier for the the DFG ﬂip. By measuring
the temperature dependence of the kinetic association and
dissociation rate constants for PDA and ponatinib, we were able
to discern the transition state energies for the association and
dissociation steps of the binding reaction according to the method
of Eyring (for details, see Supplementary Information). From
linear Eyring plots (Supplementary Fig. 4), we determined DH#,
TDS# and DG# for the association and dissociation steps
(Supplementary Table 3), which enabled us to construct detailed
thermodynamic reaction pathway models for the binding of PDA
and ponatinib to FGFR1 (Fig. 2c). For the binding of the type I
inhibitor PDA to FGFR1, we observed a free-energy barrier of
8.7 kcalmol 1 associated with the transition state. This energy
barrier is dominated by an enthalpic penalty (DH#ass¼ 16.6
kcalmol 1); however, a signiﬁcant favourable entropy
(TDS#ass¼  7.9 kcalmol 1) lowers the overall free-energy
barrier to reach the transition state. As observed for PDA, the
transition state for binding of the type II inhibitor ponatinib to
FGFR1 is also associated with an enthalpic penalty, which is
partly compensated by a favourable entropic contribution.
However, although the transition state entropy for the association
of ponatinib (TDS#ass¼  11.2 kcalmol 1) is more favourable
compared with that of PDA, it is not sufﬁcient to compensate for
the extraordinarily unfavourable DH#ass of 22.2 kcalmol 1 for
ponatinib binding, resulting in a 2.3 kcalmol 1 higher transition
state free-energy barrier (DG#ass¼ 11.0 kcalmol 1) associated
with the type II binding mode. This difference in transition state
free energy is in excellent accord with the B70-fold slower
association rate constant that we measure for ponatinib binding.
A partially unfolded intermediate in the DFG-out transition.
Localized unfolding is widely believed to contribute to the
crossing of free-energy barriers encountered during protein
motion31, and ‘cracking’ at the kinase hinge region has been
observed to be a key element in the simulated DFG-in/out
transition of EGFR kinase32. Assuming that protein
conformational energetics contribute substantially to the free-
energy changes on binding type I and type II inhibitors33, the
thermodynamic signature (unfavourable enthalpy and favourable
entropy) that we have observed for the association of ponatinib to
FGFR1 (Fig. 2, Table 1) is consistent with the proposed model of
partial unfolding, facilitating conformational transitions in
proteins. Therefore, our thermodynamic data suggest that
the transition state conformations traversed by FGFR1 during the
‘in-out’ trajectory may be partially, or locally, unfolded. The
guanidinium chloride (GdmCl)-induced unfolding transition
curve of FGFR1 monitored by the change in far-ultraviolet
circular dichroism (CD) shows two folding transitions, the ﬁrst
occurring between 1 and 2M GdmCl with accumulation of an
intermediate at B2M GdmCl. The second transition occurs
between 2 and 3.5M GdmCl, by which point the protein is
completely unfolded (Supplementary Fig. 5). Using SPR, we
determined the association rate constant of ponatinib in the
presence of 1.2M GdmCl in the phosphate-buffered saline (PBS)
running buffer to sample the partly unfolded intermediate. With
an association rate constant of 2.3 105M 1 s 1, it is
almost an order of magnitude faster than that of ponatinib in
the absence of GdmCl (kon¼ 2.4 104M 1 s 1). In contrast,
PDA binding is minimally affected by the presence of 1.2M
GdmCl, with a kon¼ 6.8 105M 1 s 1, consistent with the lack
of requirement for a ﬂip of the DFG motif for type I inhibitor
binding. The structural loosening induced by intermediate
concentrations of denaturant might be expected also to
inﬂuence dissociation rates, and this was indeed observed for
both inhibitors. Interestingly, the koff for PDA was again only
moderately affected (koff¼ 1.8 10 3 s 1, against
9.2 10 3 s 1 in the absence of GdmCl; resulting in a KD
B2-fold weaker), while that for ponatinib was dramatically
increased (koff¼ 1.8 10 2 s 1 against 1.9 10 4 s 1 in the
absence of GdmCl), leading to anB10-fold weaker KD overall in
the presence of 1.2M GdmCl. The differential effects on
association rate constant for DFG-in and DFG-out ligands
provide evidence that the partly unfolded FGFR1 intermediate
observed from the unfolding curve favours attainment of the
DFG-out conformation, and furthermore suggests that it could
serve as an intermediate of the DFG ﬂip in FGFR1.
Ponatinib binds to FGFR1 more slowly than to Abl. Ponatinib
binds to DFG-out conformations of FGFR1 and Abl kinases with
an almost identical binding mode and many conserved interac-
tions between inhibitor and protein. In view of these overall
similarities, we compared the ponatinib association rates for both
kinases, using identical SPR-based protocols, to address the
question of whether different underlying DFG-out propensities
might play a signiﬁcant role in type II inhibitor binding in these
tyrosine kinases. The binding rate of ponatinib using SPR is over
an order of magnitude faster for Abl (kon¼ 5.2 105M 1 s 1)
than for FGFR1 (kon¼ 2.4 104M 1 s 1). This faster association
rate accounts for the greater part of the roughly 10-fold higher
afﬁnity of ponatinib for Abl (KD¼ 0.9 nM) than for FGFR1
(KD¼ 7.9 nM), as the dissociation rate constants are rather similar
for the two kinases (Supplementary Table 4). Our measured
association rate for binding of the canonical type II inhibitor,
imatinib, to Abl (kon¼ 5.5 105M 1 s 1) is similar to that for
ponatinib, and is in good accord with previously reported data34.
This suggests that the difference in on-rate constant between the
two kinases that we observe for ponatinib may reﬂect a
fundamental difference in conformational energetic balance,
with a considerably higher free-energy barrier for adopting the
DFG-out conformation in FGFR1 in contrast to Abl kinase.
Dynamic cross-talk revealed by NMR and mass spectrometry.
To gain insights into the dynamic origins of slow access to the
DFG-out state in FGFR1, we employed both NMR spectroscopy
and HDX-MS. We have previously reported NMR resonance
assignments for FGFR1 kinase domain in the ligand-free state22.
Titration of either PDA or ponatinib into samples of 15N-labelled
FGFR1 kinase resulted in amide chemical shift perturbations
(CSPs) in the slow-exchange regime that were completely
saturated at 1:1 molar stoichiometry, typical of high-afﬁnity
binding in the nanomolar KD range (Fig. 3a). Unlike for the
unbound22 and the PDA-complex states of FGFR1, the ﬁrst six
residues (Asp641–Arg646) of the A-loop were observable in the
1H-15N TROSY-HSQC spectrum of the FGFR1–ponatinib
complex, indicative of altered A-loop dynamics in the ponatinib
complex compared with the unbound or PDA-bound kinase.
Comparison of 1H-15N TROSY-HSQC spectra of both PDA and
ponatinib complexes with unbound FGFR1 showed large amide
chemical shift changes for many residues. Mapping of these
perturbations onto the crystal structure of FGFR1 (PDB-code:
1FGK) shows that most of them are localized in the catalytically
important and structurally conserved regions surrounding the
active site (Fig. 3a). Signiﬁcant CSPs were observed for Ala564 in
the hinge region of both complexes, due to direct hydrogen-bond
interactions with a ring nitrogen of the inhibitor; that seen in the
ponatinib complex is substantially larger and may reﬂect a
stronger hydrogen bond. For the PDA complex, CSPs were
detected only for residues in the region of the P-loop, the
N-terminus of the aC helix, the hinge region residues, and
Ala640, which are all in close promixity to the inhibitor (Fig. 3a,
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and PDA complex (top right panel), and between unbound and ponatinib complex (bottom right panel). The CSPs 40.25 for the two complexes are
mapped on the X-ray crystal structure of unbound FGFR1 (PDB-code: 1FGK). Solid bars represent regions of b-strand secondary structure, open bars
regions of a-helical secondary structure. Selected regions of overlayed 1H-15N TROSY-HSQC plots of representative amino acids in the aC-b4 loop and
D735 in the distal aH helix are shown in small panels (left, bottom). The contour plots are colour coded as follows: unbound (black); PDA bound (blue);
ponatinib bound (red). Arrows of the corresponding color connect the same residue in different spectra. (b) Analysis of chemical exchange contributions to
transverse relaxation rates (R2,ex) measured for ligand-free (top), PDA-bound (middle) and ponatinib-bound (bottom) FGFR1 kinases at static ﬁelds of
600MHz (black), 800MHz (red) and 950MHz (blue circles), reﬂecting motions on time scales 4100ms.
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upper right panel). Interestingly, ponatinib binding revealed both
local and distal changes (Fig. 3a, lower right panel). Local CSPs
were observed in the P-loop, aC helix and hinge regions, and for
Ile620 in the catalytic loop all of which participate in direct
interactions with the inhibitor. The backbone amide nitrogen of
Asp641 (of the DFG motif) also engages in a direct hydrogen-
bond interaction with the amide carbonyl oxygen of ponatinib,
which is likely to dominate the observed CSP for this residue,
along with the change in the f torsion angle associated with the
DFG ﬂip (Fig. 3a, lower right panel; Fig. 1c). Notably, substantial
CSPs were also observed in the aC-b4 loop around Ile544, and for
Asp735 in the aH helix. These are all spatially distant from the
active site; thus, the observed chemical shift changes (Fig. 3a,
small panels) must be a result of structural or dynamic changes
propagated through an interaction network. The CSPs in the
aC-b4 loop region are of particular interest, since these amides
are likely to be highly sensitive reporters on changes in
conformation or dynamics associated with movements of the
aC helix35. By analogy with other kinases, the hydrophobic spine
network36–38 of FGFR1 is expected to be disrupted on the
reorientation of Phe642 in the inactive DFG-out state, which may
be reﬂected in perturbations seen in the chemical shifts of the
residues neighbouring His621 in the catalytic loop. Direct
contacts with the terminal methylpiperazinyl group of
ponatinib from residues including Ile620 and His621 are also
likely to contribute to the observed CSPs. Such perturbations are
not seen for the PDA-bound state (which is assumed to populate
predominantly the DFG-in conformation in solution). The large
chemical shift change we observe for Asp735 in the ponatinib-
bound complex is surprising, as Asp735 is situated in helix aH,
which is rather remote from the active site. The upﬁeld shift of
the backbone amide resonance might reﬂect subtly altered
hydrogen bonding and may report on perturbed dynamics in
the aH helix as opposed to gross conformational change (vide
infra), since the mean structures from X-ray crystallography are
essentially superimposable in this region. Further insights into the
underlying dynamics of FGFR1 in the three states were obtained
from measurements of contributions from chemical exchange
effects to the 15N transverse relaxation rates of backbone amides,
R2,ex. Using data acquired at three different magnetic ﬁeld
strengths for unbound, PDA-bound and ponatinib-bound
FGFR1, we observe particularly large ﬁeld-dependent chemical
exchange contributions to the 15N linewidth (attributable to
dynamics on time scales longer than B100ms) for the ponatinib
complex in the P-loop, compared with smaller but still signiﬁcant
effects for unbound FGFR1, and a marked suppression of
millisecond time-scale P-loop dynamics in the PDA complex
(Fig. 3b); this correlates with the additional P-loop protein–ligand
contacts that we observe in crystal structures of PDA-bound
FGFR1, but also suggests that DFG-out binding of ponatinib is
accompanied by loosening of restraining forces on P-loop
conformation. However, in contrast to the enhanced P-loop
dynamics, slow time-scale motions are markedly suppressed in
the aC-helix of the ponatinib complex compared with either
ligand-free or PDA-bound states. The R2,ex data further show the
presence of signiﬁcant slow time-scale motion in the aH helix
region of the DFG-out ponatinib complex around Asp735, in
agreement with CSP data.
Amide protection rates as measures of solvent accessibility
determined by HDX-MS39,40 can provide complementary
insights into conformational ﬂexibility. By comparing the
deuterium incorporation in the PDA and ponatinib complexes
of FGFR1 with the unbound form (Fig. 4), several regions can be
seen to exhibit signiﬁcant relative (de)protection. Both inhibitor
complexes are protected relative to ligand-free FGFR1 in the
P-loop and inter-lobe hinge, consistent with direct protection
from solvent by the ligand (Fig. 4b). The observed rate of
hydrogen exchange in the P-loop follows the order
unbound4ponatinib-bound4PDA-bound, reﬂecting the direct
interaction between the t-butyl group of PDA and the P-loop. By
comparison with the unbound and PDA-bound forms of FGFR1,
the DFG-out ponatinib complex has faster exchange kinetics in
the proximal A-loop, including the DFG motif (Fig. 4c middle
panel). In contrast, the distal stretch of the A-loop, including the
short aEF helical segment, displayes the opposite sensitivity to
DFG-in or DFG-out binding modes: it is signiﬁcantly deprotected
in the PDA complex (Fig. 4c lower panel), whereas in the
ponatinib complex this deprotection is marginal relative to
ligand-free FGFR1. This ﬁnding may indicate a certain mutual
exclusivity in the dynamic perturbations of the proximal and
distal sections of the activation loop, which is not obvious from
the X-ray crystal structure data in these regions.
Consistent with NMR chemical shift analysis, His621 in the
catalytic loop and Phe642 (of the DFG motif) display increased
hydrogen exchange in the ponatinib complex. Ponatinib-bound
FGFR1 experiences widespread loss of hydrogen-exchange
protection factors in peptides throughout the regulatory spine
(R spine)36,37. Indeed, of the ﬁve amino acids in the R spine, four
exhibit signiﬁcant increases in observed hydrogen exchange rate
in the ponatinib-bound ensemble (Fig. 4, Supplementary Fig. 9).
In contrast, just one amino acid (His621) in the R spine was seen
to have been marginally deprotected in the PDA-bound
ensemble, while Phe642 was signiﬁcantly protected. Together,
these alterations to FGFR1 solvent accessibility indicate that the
hydrophobic spine network is perturbed when the kinase adopts
the DFG-out conformation. Signiﬁcantly, and in agreement with
NMR chemical shift data, another region that showed relative
deprotection in the ponatinib-bound complex was the C-terminal
end of the aC helix and the subsequent aC-b4 loop (Fig. 4c top
panel). While the uncomplexed and PDA-bound forms show
equivalent hydrogen-exchange proﬁles, the ponatinib complex
displays a markedly greater extent of solvent exposure in this
region on average. Again consistent with NMR, the aH helix also
exhibits slight deprotection in the ponatinib complex, further
supporting the likelihood of a structural loosening of this distal
region of the kinase in the DFG-out state that is not evident from
X-ray crystal structures.
Discussion
The ﬂip between active DFG-in and inactive DFG-out states of
kinases, besides being exploitable for inhibitor design, has been
advanced as a physiologically signiﬁcant conformational transi-
tion that may have a role in modulation of the enzymatic activity
of many kinases11. This is corroborated by the observation of
DFG-out conformations in X-ray crystal structures of the
unliganded and/or autoinhibited states of a number of kinases
including Abl, c-Kit, FLT3, insulin receptor kinase and B-Raf4–8.
The inﬂuence of the protonation state of the DFG aspartate on
the kon for binding of imatinib to the DFG-out state of Abl has
been interpreted as a possible factor in the regulation of kinase
activity through facilitation of nucleotide binding and release, and
as evidence for a physiological role for the DFG ﬂip11. Our results
support a role for the protonation state of the DFG aspartate
in inﬂuencing the accessibility of the DFG-out conformation in
FGFR1, but the modest difference in pKa of the DFG aspartate in
FGFR1 (6.25) compared with that calculated for Abl (6.6)11 is
insufﬁcient to explain the wide gulf in kon for type II binding to
the two kinases. Our kinetic and thermodynamic data strongly
suggest that, in contrast to Abl41, association of type II inhibitors
is limited by an exceptionally slow DFG ﬂip in FGFR1, because a
particularly high free-energy barrier must be crossed in the
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transition between DFG-in and DFG-out states. Thus, there are
likely to be structural and/or dynamic differences between Abl
and FGFR1 that inﬂuence the accessibility of the DFG-out state.
Evidence from Eyring analysis for the elevated free energy
associated with the transition state is corroborated by the slow
association kinetics for the type II inhibitor ponatinib, and by the
differential effects on association and dissociation rate constants
for ponatinib and PDA under conditions of partial unfolding or
structural loosening in the presence of 1.2M GdmCl. This calls
into question whether it is feasible that such an innately slow
DFG ﬂip could play a physiologically relevant role in the catalytic
function of FGFR1, as has been postulated for other kinases4–8.
The thermodynamic signatures for binding to the DFG-in and
DFG-out states of FGFR1 appear to be highly distinct, with
favourable enthalpy (at relative entropic cost) for PDA binding
contrasting with a highly entropically driven interaction for
ponatinib. This rather extreme example of enthalpy–entropy
compensation42 between two inhibitors sharing very similar KDs
but strikingly different binding modes may point to greater
motional freedom as a contributory factor in the energetics of
binding of ponatinib to the DFG-out state. Indeed, our HDX-MS
data indicate an overall increased exposure of backbone amides to
solvent in the DFG-out complex relative to unbound FGFR1,
compared with predominantly enhanced protection from
exchange in the DFG-in complex with PDA. This loosening of
the structure in the DFG-out conformation is reﬂected in the
region of the aH helix, where we observed a large NMR shift for
Asp735, increased chemical exchange contributions to the NMR
R2 relaxation rates and enhanced hydrogen exchange rates for
surrounding residues in HDX-MS experiments, despite essentially
identical mean conformations as judged by X-ray crystallography.
We speculate that this effect is mediated through the aF helix,
which anchors the hydrophobic spine network. Loss of
communication through the spine as a result of the DFG ﬂip
may lead to slight destabilization of the aH helix, resulting in
increased dynamic freedom in this region. We hypothesize that
the increased mobility evident from hydrogen exchange and
NMR relaxation data in regions both proximal (P-loop) and distal
(aH helix) to the ponatinib-binding site and the DFG motif may
contribute enhanced protein conformational entropy towards
the markedly favourable gain in global entropy that characterizes
the formation of the ponatinib complex33,43,44. Conversely, the
suppression of slow time-scale motion in the aC helix that we see
from NMR R2 relaxation rates in the ponatinib-bound state
may contribute to the long residence time that characterizes the
DFG-out binding mode.
Crystal structures and molecular dynamics simulations, using
Abl kinase as a model system, suggest that displacement of the aC
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Figure 4 | Hydrogen/deuterium-exchange changes on ligand binding to FGFR1 kinase domain. (a) Difference in hydrogen exchange relative to unbound
FGFR1 for complex with PDA (left) and ponatinib (right). Protection due to ligand binding leads to a reduction in mass relative to the ligand-free form (more
negative value); deprotection results in an increase in relative mass (more positive value). Each horizontal bar represents a single peptide from FGFR1.
Vertical scale is not linear: peptides are in order of start residue from N (top) to C terminus (bottom). Peptides whose start residue is within a secondary
structural element are indicated as ﬁlled (b-sheet) or empty (a-helix) bars. Values are the sum of all nine time points sampled (each is a minimum of two
experiments and one to seven ions per peptide). Continuous shaded region denotes error at 1 s.d. Peptides from c are annotated by residue number.
(b) Data from a as a heat map projected on the unbound FGFR1 structure (PDB-code: 1FGK): complex with PDA (top) and complex with ponatinib
(bottom). Only signiﬁcant changes are shown (40.4Da difference from ligand-free form per data point)43. Data sets have been normalized to the same
scale. (c) Deuterium uptake plots for three peptides: residues Met535-Leu547, Lys638-Leu644 and Pro663-Leu672. Data points are the mean of at least
two experiments. Error bars indicate 1 s.d.
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helix away from the active site facilitates the DFG ﬂip in kinases,
with the resulting ‘aC-out’ conformation being a potential
intermediate11,36. The aC-b4 loop has been proposed to act as
an anchor for the aC helix to the catalytic core, and as a hinge for
the aC helix during the transition from active to inactive states of
protein kinases34,45. The substantial amide CSPs we observed
using NMR for residues in the aC-b4 loop in the DFG-out state
of FGFR1, coupled with signiﬁcantly enhanced solvent exchange
rates by HDX-MS, indicate that the transition from the active to
the inactive state is accompanied by a structural or dynamic
perturbation. Compared with Abl, FGFR1 contains an insert
(Gly539) C-terminal to the aC helix and a conformationally
signiﬁcant substitution in the relatively conserved ‘HxN
hairpin’35,46 that follows (HPN in many kinases including Abl;
HKN in FGFRs). The HxN hairpin may function as a pivot for
the outward movement of the aC helix that is required to
facilitate the excursion of the DFG Phe side chain towards its ‘out’
conﬁguration46. The Gly539 insert results in extension of the
C-terminal end of the aC helix of FGFR1 by around half a turn
relative to Abl (Fig. 5a), and facilitates the formation of the
molecular brake hydrogen-bond network47 between the side
chain of Asn546 and the backbone atoms of His541 of the HxN
motif. By contrast, Abl is unable to form these hydrogen bonds to
the HxN backbone. Asn546 is a key member of the triad that
forms the molecular brake in FGFR isoforms, and is the site of a
number of pathogenic gain-of-function mutations that are
implicated in developmental disorders and cancers. The
hydrogen–bond network involving Asn546 of FGFR1 would be
expected to stabilize the aC helix in its ‘in’ orientation, thereby
inhibiting the ’aC-out’ movement required to effect the DFG ﬂip
(Fig. 5b). Thus, our analysis suggests that a distributed network of
individual contributions from several regions of the kinase
structure conspires to hinder the DFG ﬂip in FGFR1, and that
the most important of these is likely to reside in the aC-b4 loop
region. This is interesting in light of a recent report that the
N550K mutation in FGFR2 (equivalent to Asn546 in FGFR1)
confers resistance to the type I inhibitors PD173074 and
dovitinib, but not to ponatinib, which displays enhanced
inhibitory potency against this mutant relative to wild-type in
BaF3 cell proliferation assays48. Our insights into the structural
and dynamic inﬂuences on the DFG ﬂip in FGFR1 corroborate
the important role of the molecular brake in inhibiting basal
kinase activity in unphosphorylated FGFRs, and imply that its
function (and its release by pathogenic mutations) may be
intimately associated with its ability to suppress the catalytically
signiﬁcant DFG ﬂip11 by inhibiting the outward movement of the
aC helix.
Methods
Protein expression and puriﬁcation. Human FGFR1 consisting of residues
Ala458-Glu765 with an engineered TEV-cleavable N-terminal 6His tag and
mutations Cys488Ala and Cys584Ser was co-expressed in Escherichia coli with
protein tyrosine phosphatase 1B (PTP1B) and puriﬁed by sequential immobilized
metal afﬁnity chromatography (IMAC, QIAGEN NiNTA), ion exchange
(ResourceQ) and size exclusion chromatography49. The hexa-histidine tag was
cleaved from protein by overnight treatment with TEV protease and concomitant
dialysis, immediately after the IMAC step. Puriﬁed protein in a buffer comprising
20mM Tris-HCl, pH 8.0, 20mM NaCl, 2mM TCEP, was snap frozen in liquid
nitrogen and stored at  80 C. For NMR studies, an additional mutation
(Asp623Ala) was introduced to improve the yield of stable isotope-labelled FGFR1
kinase protein22. Uniform isotopic labelling was achieved by growing E. coli BL21
(DE3) Star cells in D2O-based M9 minimal medium supplemented with 15NH4Cl
(Cambridge Isotope Laboratories or Sigma Aldrich) together with U-[1H,13C]- or
(for fully deuterated samples) U-[2H,13C]-glucose (Cambridge Isotope Laboratories
or Sigma Aldrich) as sole nitrogen and carbon sources, respectively. Puriﬁcation
was by IMAC and ion exchange chromatography; the 6His tag was not cleaved
from the protein used for NMR. Human Abl consisting of residues Ser248-Val534
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b
Figure 5 | The role of the aC-b4 loop and molecular brake regions in the DFG ﬂip of FGFR1. (a) Comparison of aC-b4 loop and molecular brake regions
in FGFR1 and Abl kinase complexes with ponatinib. The structures of the FGFR1/ponatinib complex (PDB ID: 4V01) and the Abl/ponatinib
complex (PDB ID: 3OXZ) are displayed in dark green and grey, respectively, with the bound ponatinib inhibitors displayed, respectively, in light green and
grey. Relative to Abl, the aC helix of FGFR1 extends approximately one-half turn further, in part due to insertion of a Gly at position 539, and the ‘HxN
hairpin’ contains a Lys rather than a Pro at the middle position. The molecular brake of FGFR1 is engaged via hydrogen bonds (dotted lines) from the side
chain of Asn546 and likely inhibits the outward motion of helix aC in FGFR1, whereas Abl, with a Gln at the equivalent position and lacking the Gly insert at
position 539, is unable to form the molecular brake interactions. (b) Schematic illustration of the interplay between the DFG ﬂip, outward movement of the
aC helix and the proposed role of the Asn546 molecular brake hydrogen bonds in FGFR1. The Asn546 hydrogen bonds (of which Abl lacks an equivalent)
may need to be transiently disengaged (scissors) to facilitate the aC-out, and hence DFG-out, movements. View in b as if from the left-hand side of a.
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with an engineered TEV-cleavable N-terminal 6His tag and mutation Asn355Ser
was expressed and puriﬁed as described50 with minor modiﬁcations. For
biophysical studies, the 6His tag was retained intact for both kinases as it was
used for immobilization on a nitrilotriacetic acid (NTA) sensor chip.
Crystallization, crystallographic data collection, structure determination and
reﬁnement. Growth of FGFR1 crystals were grown by the hanging drop vapour
diffusion method at 4 C by mixing equal volumes of puriﬁed FGFR1 at
10mgml 1 with a reservoir solution comprising 18–20% PEG8000 (w/v), 200mM
ammonium sulphate, 100mM PCTP, pH 6.75 and 20% ethylene glycol (v/v) so as
to obtain a 2 ml drop49. Crystals were allowed to grow for at least 1 week before
harvesting into a soaking solution comprising 22% PEG8000 (w/v), 200mM
ammonium sulphate, 100mM PCTP, pH 6.75, 20% ethylene glycol (v/v) and 1mM
PDA or 1mM dovitinib plus 1% DMSO (v/v). Soaks were incubated overnight. All
work was carried out at 277K. Crystals were ﬂash frozen in a stream of nitrogen
gas at 100K directly from the drop. Diffraction data were collected in-house on a
Rigaku FRE rotating anode generator (l¼ 1.54Å) equipped with a Saturn 944
CCD detector or at Diamond Light Source on beamline I04 (l¼ 0.92Å) using an
ADSC Quantum 315 CCD detector. Data were processed with XDS and AIMLESS
as implemented within autoPROC51 and XIA2 (ref. 52), respectively. The FGFR1–
PDA and FGFR1–dovitinib crystals belong to the space group C1 2 1 and contain
two complexes per asymmetric unit. The structures were solved by molecular
replacement using the programme AMORE53 and an in-house FGFR1 structure as
a search model. The structures were completed with iterative rounds of manual
building in Coot54 interspersed with reﬁnement using the programmes REFMAC55
and autoBUSTER applying NCS restraints and TLS. Quality checks were carried
out using the validation tools in Coot and MolProbity56, while the compound
stereochemistry was checked against the Cambridge Structure Database (CSD)57
using Mogul58. Ramachandran analysis revealed 93.6% (favoured), 6.0% (allowed)
and 0.4% (generously allowed) for the FGFR1–PDA complex and 91.3%
(favoured), 7.3% (allowed), 1.0% (generously allowed) and 0.4% (disallowed) for
the FGFR1–dovitinib complex. Crystallographic statistics indicating data and
model stereochemical quality are given in Supplementary Table 5. The ﬁnal
structures have been deposited in the PDB with ID code: FGFR1 PDA complex,
5A4C; FGFR1–dovitinib complex, 5A46. All structural ﬁgures were prepared using
PyMOL (Schro¨dinger LLC).
Surface plasmon resonance. Non-phosphorylated, histidine-tagged FGFR1 and
non-phosphorylated, histidine-tagged Abl were immobilized as the ligand onto
NTA sensor chips using a capture coupling method59. The NTA surface was ﬁrst
activated with 500 mMNiSO4 in immobilization buffer. The carboxymethyl dextran
surface was then activated with a 1:1 ratio of 0.4M EDC and 0.1M NHS. Hexa-
histidine-tagged protein was diluted into immobilization buffer to a concentration
of 30 mgml 1, and immobilized onto the surface with a 7-min injection.
Remaining activated groups were blocked with 0.1M Tris, pH 8.0. Typical
immobilization levels ranged from 6,000 to 8,000 resonance units (RU). PBS, pH
7.4, 50mM EDTA and 0.05% Surfactant P20 (v/v) (for Abl supplemented with 10%
glycerol (v/v)) were used as immobilization buffer. Typical immobilization levels
ranged from 3,800 to 8,000 RU. SPR experiments were performed using the Biacore
3000, Biacore S51 and Biacore T200 biosensors (GE Healthcare), with NTA and
series S NTA sensor chips (GE Healthcare). All FGFR1 binding experiments were
done using PBS (pH range 7.0–7.4), 50 mM EDTA, 0.05% Surfactant P20 (v/v) and
1% DMSO (v/v) or 50mM Bis-Tris (pH range 5.5–6.5), 100mM NaCl, 50 mM
EDTA, 0.05% Surfactant P20 (v/v) and 1% DMSO (v/v), as running buffer. All Abl
binding experiments were conducted using PBS, pH 7.4, 50 mM EDTA, 0.05%
Surfactant P20 (v/v), 10% glycerol (v/v) and 1% DMSO (v/v) as running buffer.
Compounds as DMSO stocks were diluted in DMSO to concentrations 100-fold
higher than the ﬁnal assay concentration. Finally, they were diluted 1:100 (v/v) in
running buffer without DMSO to achieve the target concentration resulting in a
ﬁnal DMSO concentration of 1% (v/v).
SPR kinetic analysis. To determine the rate constants of association (kon) or
dissociation (koff), either multi-cycle or single-cycle SPR experiments were per-
formed at 298K. Single-cycle kinetic analysis was done at a constant ﬂow rate of
60ml min 1 in running buffer. The highest compound concentration varied, but
for all analytes ﬁve sequential injections with constant injection time and a con-
stant dilution factor were done. All analyte concentrations were injected in one
cycle, one after the other for 120 s with a short dissociation phase in between
injections (B60 s) and with a longer dissociation phase at the end of the cycle
(1,000 to 20,000 s that varied depending on the expected dissociation rate constant
of the analyte). Zero-buffer blank injections were included for referencing. Biacore
T200 evaluation software and BIAevaluation 4.1 software, respectively, were used
for processing and analysing data. Rate constants were calculated globally from the
obtained sensorgram data by ﬁtting to a 1:1 interaction model. Representative
sensorgrams are shown in Supplementary Fig. 6. Multi-cycle kinetic analysis was
carried out as previously described59. Binding afﬁnities (KD) were calculated from
the equation KD¼ koff/kon.
SPR thermodynamic analysis. The thermodynamic parameters of ponatinib
and PDA binding were determined by performing single-cycle kinetic analysis at
different temperatures as described above. SU5402 showed faster association
and dissociation rate constants, thereby complicating kinetic analysis at higher
temperatures. Binding afﬁnities (KD) were therefore determined from dosage
experiments and binding responses at equilibrium were ﬁt to a 1:1 steady-state
afﬁnity model available within the Scrubber 2 software (BioLogic Software Ltd.,
Campbell, Australia). For each analysed ligand, rate constants and/or afﬁnity were
determined at a minimum of six different temperatures between 281 and 308K.
Association constants (KA) derived from kinetic or steady-state analysis were
plotted as ln (KA) against 1/T, according to the integrated van’t Hoff equa-
tion60,61—equation (1).
ln KA=KA0ð Þ ¼ DH0 T0DCp
 
1=T0  1=Tð ÞþDCpln T=T0ð Þ
 
=R ð1Þ
where T0 is an arbitrarily selected reference temperature, KA0 is the association
constant at temperature T0, and DH0 is the van’t Hoff enthalpy at temperature T0.
DCp is the temperature-independent heat capacity change (constrained to the
experimentally determined values of  359 and  172 calmol 1K 1
(Supplementary Fig. 7) for the analysis of PDA and SU5402, respectively) and
R¼ 1.986 calmol 1 K 1. DH0 was determined by non-linear ﬁtting of
equation (1) to the experimental data using Prism 5.1 (GraphPad Software, Inc,
La Jolla, USA). Transition state thermodynamic quantities were determined from
the kinetic association (kon) and dissociation (koff) rate constants as previously
described64 by plotting ln (kh/kBT) versus 1/T according to the linear Eyring
equation (2).
ln kh=kBTð Þ ¼ DH=RT þDS=R ð2Þ
where h¼ 6.63 10 34 J s and kB¼ 1.38 10 23 J K 1 are the Planck and
Boltzmann constants, respectively. Here k is either the association rate constant
(kon) or the dissociation rate constant (koff). DH and DS are the changes in free
enthalpy and entropy of binding, respectively, while the superscript ‘*’ denotes that
these refer to a transition state. T is the absolute temperature, and
R¼ 1.986 calmol 1 K 1. DH* and DS* were determined by linear ﬁtting of
equation (2) to the experimental data using Prism 5.1 (Supplementary Fig. 4).
Isothermal titration calorimetry. ITC experiments were carried out using an
ITC200 instrument (Microcal Inc., GE Healthcare)59. Final ligand concentrations
were achieved by diluting ligand stock solutions in DMSO 1:50 (v/v) in the
experimental buffer, resulting in a ﬁnal DMSO concentration of 2% (v/v). Protein
concentration was determined by measuring the absorbance at 280 nm. DMSO
concentration in the protein solution was adjusted to 2% (v/v). ITC measurements
were routinely performed at 25 C in 20mM Tris, pH 7.8, 20mM NaCl, 2mM
TCEP and 2% DMSO (v/v). The titrations were performed on 10 20 mM FGFR1
in the 200 ml sample cell using 2 ml injections of 0.1 0.2mM ligand solution
every 120 s. To correct for heats of dilution and mixing, the ﬁnal baseline consisting
of small peaks of identical size at the end of the experiment was subtracted.
Representative ITC titrations are shown in Supplementary Fig. 2. To determine the
heat capacity DCp of ligands binding to FGFR1, ITC titrations were performed as
described above at 10, 15, 20, 25, 30 and 35 C. Binding enthalpies derived from
ITC experiments were plotted as DH against T and DCp are given by the slope of
the linear regression analysis according to equation (3) (Supplementary Fig. 7):
DH T2ð Þ ¼ DH T1ð ÞþDCp T2 T1ð Þ ð3Þ
Equilibrium chemical denaturation of FGFR1 using far-ultraviolet CD
Spectroscopy. Far-ultraviolet CD spectra (190–260 nm) of FGFR1 kinase domain
were obtained at different concentrations of GdmHCl. Spectra were measured on a
JASCO J-810 spectropolarimeter at 293 K in 10mM sodium phosphate buffer, pH
7.4; the concentration of FGFR1 used throughout was 2.8 mM. Unfolding experi-
ments on FGFR1 kinase domain were completed by diluting the native FGFR1
protein sample with sequential additions of a second stock solution containing
FGFR1 protein unfolded in 5M GdmHCl, similarly buffered in 10mM sodium
phosphate, pH 7.4. The concentration of GdmHCl was determined using refractive
index measurements as described62. Appropriate buffer blanks containing the
corresponding concentration of denaturant were subtracted from all spectra, to
account for the small contribution to the observed signal made by buffer. Molar
ellipticity values at 222 nm obtained at varying denaturant concentrations were
analysed using non-linear least-squares regression analysis, employing a modiﬁed
version of the equation described in Morjana et al.63:
y ¼ yn þmn D½ ð Þþ yi þmi D½ ð ÞKn!ið Þð
þ yu þmu D½ Kn!i Ki!uÞð Þ= 1þKn!i þðKn!i Ki!uÞð Þð
ð4Þ
where yn, yi, yu are the signals of the native (n), intermediate (i) and unfolded (u)
states, respectively, at zero denaturant concentration ([D]), mn, mi, mu represent
dy/d[D] or slopes of the native, intermediate and unfolded state signals, respectively,
Kn-i¼ exp (DGn-imn-i [D])/RT, Ki-u¼ exp (DGi-umi-u [D])/RT,
where DG represents the free-energy change of the indicated transition, m is the
slope of the free-energy change versus [D] for the indicated transition, R is the gas
constant and T is the experimental temperature.
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NMR spectroscopy. Uniformly 13C/15N/2H-labelled samples of unbound FGFR1
and ligand-bound FGFR1–ponatinib and FGFR1–PDA complexes (1:1) were
prepared22 as 0.35mM solutions in 450 ml of 95% H2O and 5% D2O, 50mM
sodium phosphate, 0.1mM EDTA, 2mM dithiothreitol and 0.02% sodium azide
(pH 7.0). PDA and ponatinib were added from concentrated stock solutions
dissolved in DMSO-d6. NMR spectra were recorded at 298K on Bruker Avance
600MHz, Avance III 800 and Avance III HD 950MHz spectrometers equipped
with z-axis pulsed-ﬁeld gradient TCI CryoProbes. TROSY-based detection schemes
were used throughout as previously described22. Backbone resonance assignments
for the FGFR1–PDA and FGFR1–ponatinib complexes followed standard triple-
resonance strategies with two- and three-dimensional experiments using TROSY
detection22, and will be reported elsewhere. The presence of backbone amide
conformational exchange effects was studied by measuring the relaxation rates of
the slowly relaxing 15N-{1H} TROSY doublet component using a Hahn-echo-based
sequence optimized for deuterated proteins as described in Lakomek et al.64,65. All
NMR data were processed using the NMRPipe suite of programmes66 and analysed
with CARA67 to obtain assignments. 15N relaxation decay curves were ﬁtted using
a simplex search minimization and Monte Carlo estimation of errors.
Hydrogen/deuterium-exchange mass spectrometry. Hydrogen exchange was
performed using an HDX Manager (Waters Corp.) equipped with a CTC PAL
sample handling robot (LEAP Technologies). Brieﬂy, FGFR1 kinase domain
(52.3 mM) in protonated aqueous buffer (20mM Tris, 20mM NaCl, 2mM TCEP,
pH 7.4) was incubated with ligand (100 mM) or DMSO. This gave 99.7 and 99.8%
bound FGFR1 following dilution in the labelling solution for ponatinib (KD¼ 7.7
nM) and PDA (KD¼ 5.7 nM), respectively. Hydrogen exchange was initiated by
dilution of 20-fold into deuterated buffer (20mM Tris, 20mM NaCl and 2mM
TCEP, pD 7.4) at 293 K. After incubation between 10 s and 2 h, hydrogen-exchange
was quenched by mixing 1:1 with 100mM potassium phosphate to a ﬁnal pH of
2.55 at 274K. Sample was immediately digested by a pepsin–agarose column
(Poroszyme) and the resulting peptides separated on a C18 column (1 100mm
ACQUITY BEH 1.7 mm, Waters Corp.) with a linear gradient of acetonitrile
(3–40%) supplemented with 0.1% formic acid. Peptides were analysed with a
Synapt G2 mass spectrometer (Waters Corp.). Peptides were identiﬁed by MSE
fragmentation, yielding coverage of 97% of the His-tagged fusion protein construct
of FGFR1 kinase domain with a high degree of redundancy (Supplementary Fig. 8).
Peptides from Fig. 4c were conﬁrmed by targeted tandem mass spectrometry
fragmentation. No correction was made for back-exchange, and all results are
reported as relative deuterium level. Deuterium incorporation was measured in
DynamX (Waters Corp.) and data normalization was calculated with in-house
software written in MatLab (Mathworks) and Python. Structural representations
were generated with PyMol and plots in Fig. 4 prepared with Prism. Hydrogen/
deuterium-exchange was represented in Fig. 4b by calculating the mean deuteration
level per amino acid, according to equation (5).
Mj ¼ 1n
Xn
1
1
q
Xt
0
mti m0i
  ð5Þ
Where Mj is the mean deuteration level at amino acid j, n is the number of
overlapping peptides, q is the number of exchangeable amides for peptide species
i, mti is the isotopic weighted midpoint at time t and m
0
i is the midpoint at time 0
(undeuterated).
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